Cost of illness and economic burden of chronic lymphocytic leukemia

Orphanet Journal of Rare Diseases

Tom Stargardt¹  Jonas Schreyögg¹  Frank Verheyen²  Roland Linder²  Taika Koch¹  Carl Rudolf Blankart¹ 

[1] Hamburg Center for Health Economics, Universität Hamburg, Esplanade 36, D-20354, Hamburg, Germany;WINEG—Scientific Institute of the Techniker Krankenkasse (TK) for Benefit and Efficiency in Health Care, Bramfelder Straße 140, D-22305, Hamburg, Germany

关键词: Elixhauser comorbidity groups;    Case–control design;    Economic evaluation;    Administrative data;    Routine data;    CLL;   

Others  :  864112
DOI  :  10.1186/1750-1172-8-32

 received in 2012-09-11, accepted in 2013-02-11,  发布年份 2013

【 摘 要 】

Background

Chronic lymphocytic leukemia (CLL) is a slowly progressing but fatal disease that imposes a high economic burden on sickness funds and society. The objective of this study was to analyze and compare the direct and indirect costs of CLL in Germany from the perspective of the sickness funds and society and analyze the burden of the disease.

Methods

Using a database of 7.6 million enrolled individuals, we identified 4198 CLL patients in 2007 and 2008. The costs attributable to CLL were estimated using a case–control design with a randomly selected control group of 150 individuals per combination of age and sex. We used the bootstrap approach to estimate uncertainties in costs estimated. We employed generalized estimating equation regression models and count data models to test for differences in costs and healthcare utilization.

Results

The cost attributable to CLL for each prevalent case amounts to €4946 from the payer’s perspective and €7910 from a societal perspective. Inpatient hospital stays and pharmaceuticals are the main cost drivers of the disease. The economic burden of disease in Germany was estimated to be approximately €201 million per year for the sickness funds and €322 million for society.

Conclusions

Compared with common diseases, such as diabetes or COPD, the economic burden of CLL is considerably lower. However, the cost of treatment per case is about twice as high as the cost per case for these common diseases, even though treatment is only performed in the later stages of CLL. With new healthcare technologies, the aging population, and the increasing incidence of the disease, it is likely that the economic burden of the disease will continue to grow.

【 授权许可】

   
2013 Blankart et al; licensee BioMed Central Ltd.

【 图 表 】

【 参考文献 】

• [1]Dighiero G, Binet J-L: When and How to Treat Chronic Lymphocytic Leukemia. N Engl J Med 2000, 343:1799-1801.
• [2]Orphanet: Prevalence of rare diseases: Bibliographic data. Paris: Orphanet; 2011.
• [3]National Cancer Institute: SEER cancer statistics. Bethesda: National Cancer Institute; 2008.
• [4]Hallek M, Emmerich B: Chronische lymphatische Leukämie/lymphoplasmozytoides Lymphom. In Kompendium Internistische Onkologie. Edited by Schmoll H-J, Höffken K, Possinger K. Berlin: Springer; 2006:2845-2886.
• [5]Stephens JM, Gramegna P, Laskin B, Botteman MF, Pashos CL: Chronic Lymphocytic Leukemia: Economic Burden and Quality of Life: Literature Review. Am J Ther 2005, 12:460-466.
• [6]Roll K, Stargardt T, Schreyögg J: Zulassung und Erstattung von Orphan Drugs im internationalen Vergleich. Gesundheitswesen 2011, 73:504,514.
• [7]Redaelli A, Stephens JM, Laskin BL, Pashos CL, Botteman MF: The burden and outcomes associated with four leukemias: AML, ALL, CLL and CML. Expert Rev Anticancer Ther 2003, 3:311-329.
• [8]Zeger SL, Liang K-Y, Albert PS: Models for Longitudinal Data: A Generalized Estimating Equation Approach. Biometrics 1988, 44:1049-1060.
• [9]Efron B: Bootstrap Methods: Another Look at the Jackknife. Ann Stat 1979, 7:1-26.
• [10]Bundesvereinigung K: Statistische Basisdaten zur vertragszahnärztlichen Versorgung. Köln: Kassenzahnärztliche Bundesvereinigung; 2011.
• [11]Bundesamt S: Gesundheitsausgabenrechnung. Bonn: Statistisches Bundesamt; 2008.
• [12]Liljas B: How to Calculate Indirect Costs in Economic Evaluations. PharmacoEconomics 1998, 13:1-7.
• [13]Statistisches Bundesamt: Entwicklung der Bruttoverdienste. Wiesbaden: Statistisches Bundesamt; 2007:8.
• [14]Krauth C, Hessel F, Hansmeier T, Wasem J, Seitz R, Schweikert B: Empirical standard costs for health economic evaluation in Germany -- a proposal by the working group methods in health economic evaluation. Gesundheitswesen 2005, 67:736-746.
• [15]Vuong QH: Likelihood Ratio Tests for Model Selection and Non-Nested Hypotheses. Econometrica 1989, 57:307-333.
• [16]Elixhauser A, Steiner C, Harris DR, Coffey RM: Comorbidity measures for use with administrative data. Med Care 1998, 36:8-27.
• [17]Quan H, Sundararajan V, Halfon P, Fong A, Burnand B, Luthi JC, Saunders LD, Beck CA, Feasby TE, Ghali WA: Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data. Med Care 2005, 43:1130-1139.
• [18]Tsiodras S, Samonis G, Keating MJ, Kontoyiannis DP: Infection and Immunity in Chronic Lymphocytic Leukemia. Mayo Clin Proc 2000, 75:1039-1054.
• [19]Reis A, Ihle P, Paulus U, Ferber LV, Diehl V, Walshe R: Cost of illness of malignant lymphoma in Germany. Eur J Cancer Care (Engl) 2006, 15:379-385.
• [20]Akobundu E, Ju J, Blatt L, Mullins CD: Cost-of-illness studies: a review of current methods. PharmacoEconomics 2006, 24:869-890.
• [21]Slager SL, Goldin LR, Strom SS, Lanasa MC, Spector LG, Rassenti L, Leis JF, Camp NJ, Kay NE, Vachon CM, et al.: Genetic Susceptibility Variants for Chronic Lymphocytic Leukemia. Cancer Epidemiol Biomarkers Prev 2010, 19:1098-1102.
• [22]Larg A, Moss JR: Cost-of-illness studies: a guide to critical evaluation. PharmacoEconomics 2011, 29:653-671.
• [23]World Health Organization: WHO guide to identifying the economic consequences of disease and injury. Geneva: World Health Organization; 2009.
• [24]Schreyögg J, Stargardt T, Tiemann O, Busse R: Methods to determine reimbursement rates for diagnosis related groups (DRG): A comparison of nine European countries. Health Care Manag Sci 2006, 9:215-223.
• [25]Roche: Annual Report 2001. Basel: F. Hoffmann-La Roche Ltd; 2001.
• [26]Roche: Annual Report 2011. Basel: F. Hoffmann-La Roche Ltd; 2011.
• [27]Köster I, von Ferber L, Ihle P, Schubert I, Hauner H: The cost burden of diabetes mellitus: the evidence from Germany—the CoDiM Study. Diabetologia 2006, 49:1498-1504.
• [28]Leal J, Luengo-Fernández R, Gray A, Petersen S, Rayner M: Economic burden of cardiovascular diseases in the enlarged European Union. Eur Heart J 2006, 27:1610-1619.
• [29]Yu W, Ravelo A, Wagner TH, Phibbs CS, Bhandari A, Chen S, Barnett PG: Prevalence and Costs of Chronic Conditions in the VA Health Care System. Med Care Res Rev 2003, 60:146S-167S.
• [30]Schubert I, Koster I, Kupper-Nybelen J, Ihle P: Health services research based on routine data generated by the SHI, Potential uses of health insurance fund data in health services research. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz 2008, 51:1095-1105.
• [31]Seshamani M, Gray A: Ageing and health-care expenditure: the red herring argument revisited. Health Econ 2004, 13:303-314.
• [32]Stollenwerk B, Stock S, Siebert U, Lauterbach KW, Holle R: Uncertainty Assessment of Input Parameters for Economic Evaluation: Gauss’s Error Propagation, an Alternative to Established Methods. Med Decis Making 2010, 30:304-313.
• [33]Steinbusch PJM, Oostenbrink JB, Zuurbier JJ, Schaepkens FJM: The risk of upcoding in casemix systems: A comparative study. Health Pol 2007, 81:289-299.